Nav: Home

Nutrient offers hope to stop deadly march toward cirrhosis, liver cancer

April 19, 2017

CORVALLIS, Ore. - A new study suggests that one type of omega 3 fatty acid offers people who are obese or have a poor diet a chance to avoid serious liver damage.

This is something that no available drug can accomplish, and can otherwise only be obtained by significant weight loss based on a very healthy diet.

The findings, published by researchers from Oregon State University today in PLOS ONE, were based on a study done with laboratory animals. They could be significant, researchers say, since millions of people in the developed world try, and fail, to sustain weight loss or eat an optimal diet.

Supplements of DHA, one of the most critically important of the omega 3 fatty acids, were shown to stop the progression of nonalcoholic steatohepatitis, or NASH, into more serious and life-threatening health problems such as cirrhosis or liver cancer. This took place even with the continued consumption in lab animals of what scientists call a "western" diet - one that's high in fat, sugar and cholesterol.

NASH, which is characterized by liver inflammation, oxidative stress and fibrosis, is a substantial risk factor for cirrhosis and liver cancer. It's predicted to be the leading cause of liver transplants by 2020, and the FDA currently has no approved medical treatments for it.

Based in large part on consuming the "western diet," nearly 80 million adults and 13 million children in the United States are obese, and about 30 percent of the nation's population is estimated to have some form of chronic fatty liver disease.

"Considering there are no FDA-approved ways to stop NASH progression, other than weight loss therapy, this supplement may be of significant help," said Donald Jump, a professor in the OSU College of Public Health and Human Sciences, and principal investigator with the Linus Pauling Institute.

"In the time frame that we studied, DHA supplementation was not able to achieve full remission of NASH, but it did stop it from getting worse. NASH is a serious disease, an enormous health care cost and we need to put the brakes on it. There's clear evidence this might help."

Over one 10-year study period, cirrhosis and liver-related deaths occurred in 20 percent and 12 percent of NASH patients, respectively.

Research has also shown that when humans with NASH are examined, they have very low levels of omega 3 fatty acids. When those levels are raised, the disease progression stops.

Omega 3 fatty acids regulate important biological pathways, including fatty acid synthesis, oxidation, and breakdown of triglycerides, or fats in the blood. A natural nutrient, DHA appears to be one of the most significant of the omega 3 fatty acids, and plays a role in repairing liver damage.

The highest levels of DHA are found in oily fish such as salmon, mackerel, tuna and sardines, and to a much lesser extent in some foods such as poultry, liver, egg yolks, and some types of algae. DHA is also increasingly being included in some prenatal vitamin and mineral formulas because of studies showing its critical importance to a developing fetus.

The current medical approach to NASH is based on lifestyle management, including diet and exercise. If successful and sustained, research indicates such approaches can completely reverse liver damage. However, in this study researchers noted that "this treatment, while ideal for clinical use, is likely not sustainable in NASH patients due to poor compliance."

EPA, another valuable omega 3 fatty acid, has not been found to lower liver fat and fibrosis in humans, Jump said, probably due to the poor conversion in humans of EPA to DHA.

DHA is a readily available supplement and safe to use, researchers say. Referring to the use of DHA supplementation to address problems with NASH, the researchers said in their report that, "This scenario will likely be used clinically since patient compliance to low-fat, low-sucrose dietary recommendations has historically been poor."
-end-
This research was supported by the U.S. Department of Agriculture and the National Institutes of Health.

Oregon State University

Related Liver Cancer Articles:

Report looks at liver cancer, fastest-growing cause of cancer deaths in US
A new report provides an overview of incidence, mortality, and survival rates and trends for liver cancer, a cancer for which death rates have doubled in the United States since the mid-1980s
The IT-LIVER European consortium unveils new TGF-beta functions in liver cancer
Recent research results from the European consortium IT-Liver provide a better understanding of the role of the TGF-beta cytokine in liver cancer.
A novel molecular link between cholesterol, inflammation and liver cancer
Hepatocellular carcinoma (HCC) is a deadly disease with no effective cure that develops in the context of liver diseases associated with chronic inflammation.
One more piece in the puzzle of liver cancer identified
Manuela Baccarini and her team at the Max F. Perutz Laboratories (MFPL) of the University of Vienna and Medical University of Vienna are one step closer to unraveling the mechanisms behind liver cancer.
New approach to liver transplantation: Using a damaged liver to replace a dying liver
There's new hope for patients with liver disease who are waiting for a donor liver to become available for transplantation.
Damage to tiny liver protein function leads to heart disease, fatty liver
A UCF College of Medicine researcher has identified for the first time a tiny liver protein that when disrupted can lead to the nation's top killer -- cardiovascular disease -- as well as fatty liver disease, a precursor to cancer.
Targeted treatment for liver cancer under way
Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.
Transplanted liver cells protect against liver failure after massive hepatectomy surgery
Because liver failure often occurs after an extensive hepatectomy, researchers using animal models investigated safer ways to transplant liver cells post-extensive hepatectomy found that rather than transplanting cells into the liver portal vein, transplantation into an extra-hepatic site, such as the intra-mesentery, a fold of membranous tissue on the posterior wall of the abdominal cavity attached to the intestinal tract, can help protect against post-operative liver failure and aid in survival of the remaining liver.
Scientists root out the 'bad seeds' of liver cancer
Researchers have found the 'bad seeds' of liver cancer and believe they could one day reprogram them to remain responsive to cancer treatment, a new USC study has found.
Retroviral RNA may play a part in liver cancer
Researchers have found that retroviral long-terminal-repeat (LTR) promoters -- a type of repetitive element that are widely distributed in the human genome -- are highly activated in hepatocellular carcinomas, the most common type of liver cancer.

Related Liver Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".